ProPhase Labs, Inc. Increase (Decrease) in Income Taxes Payable
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Income Taxes Payable of $510.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-19
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was -$2.00K.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was $512.00K.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was -$10.00K.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was -$1.08M.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for fiscal 2025 was -$1.71M.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for fiscal 2024 was -$1.29M.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for fiscal 2023 was -$911.00K, a 131.65% decline from fiscal 2022.
- ProPhase Labs, Inc. increase (decrease) in income taxes payable for fiscal 2022 was $2.88M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month | Increase (Decrease) in Income Taxes Payable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $510.00K 10-Q · filed 2026-08-19 | $500.00K derived: sum of 3 quarters · filed 2026-08-19 | -$583.00K derived: sum of 4 quarters · filed 2026-08-19 | |
| 2026-03-31 | $512.00K 10-Q/A · filed 2026-07-09 | $502.00K derived: sum of 2 quarters · filed 2026-07-09 | -$581.00K derived: sum of 3 quarters · filed 2026-07-09 | -$671.00K derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$1.09M derived: sum of 2 quarters · filed 2026-06-01 | -$1.18M derived: sum of 3 quarters · filed 2026-08-19 | -$1.71M 10-K · filed 2026-06-01 | |
| 2025-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$1.17M derived: sum of 2 quarters · filed 2026-08-19 | -$1.70M 10-Q · filed 2025-11-19 | -$1.98M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | -$613.00K 10-Q · filed 2026-08-19 | -$901.00K derived: sum of 3 quarters · filed 2026-08-19 | -$1.29M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-03-31 | -$523.00K 10-Q/A · filed 2026-07-09 | -$811.00K derived: sum of 2 quarters · filed 2026-07-09 | -$1.20M derived: sum of 3 quarters · filed 2026-07-09 | -$1.54M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2024-12-31 | -$288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$674.00K derived: sum of 2 quarters · filed 2026-06-01 | -$1.02M derived: sum of 3 quarters · filed 2026-06-01 | -$1.29M 10-K · filed 2026-06-01 | |
| 2024-09-30 | -$386.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$731.00K derived: sum of 2 quarters · filed 2025-11-19 | -$1.00M 10-Q · filed 2025-11-19 | -$1.03M derived: sum of 4 quarters · filed 2025-11-19 | |
| 2024-06-30 | -$345.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$618.00K 10-Q · filed 2025-08-13 | -$648.00K derived: sum of 3 quarters · filed 2025-08-13 | $269.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$273.00K 10-Q · filed 2025-05-20 | -$303.00K derived: sum of 2 quarters · filed 2025-05-20 | $614.00K derived: sum of 3 quarters · filed 2025-05-20 | -$843.00K derived: sum of 4 quarters · filed 2025-05-20 | |
| 2023-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $887.00K derived: sum of 2 quarters · filed 2025-04-01 | -$570.00K derived: sum of 3 quarters · filed 2025-04-01 | -$911.00K 10-K · filed 2025-04-01 | -$912.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $917.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$540.00K derived: sum of 2 quarters · filed 2024-11-13 | -$881.00K 10-Q · filed 2024-11-13 | -$5.03M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.80M 10-Q · filed 2024-08-14 | -$5.95M derived: sum of 3 quarters · filed 2024-08-14 | -$4.39M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$341.00K 10-Q · filed 2024-05-10 | -$4.49M derived: sum of 2 quarters · filed 2024-05-10 | -$2.94M derived: sum of 3 quarters · filed 2024-05-10 | -$436.00K derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$2.60M derived: sum of 2 quarters · filed 2024-03-29 | -$95.00K derived: sum of 3 quarters · filed 2024-03-29 | $2.88M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.06M derived: sum of 2 quarters · filed 2023-11-13 | $7.03M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $5.47M 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | $2.97M 10-Q · filed 2023-05-12 | ||||
| 2017-12-31 | -$1.35M 10-K/A · filed 2018-08-20 | -$848.00K 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |